Floatz logo

Solu-Cortef

Peritoneal Neoplasm

National Cancer Institute (NCI)Phase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Peritoneal Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
AstraZeneca
Phase 2BB
Benadryl
National Cancer Institute (NCI)
Phase 2B
Enzastaurin
Eli Lilly and Company
Phase 2B
RANITIDINE
National Cancer Institute (NCI)
Phase 2B
Semaxanib
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Solu-Cortef is also rated in:

congenital adrenal hyperplasiaDormant
A
Indicative ·
81 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
BB
Indicative ·
68 / 100
View asset →
myelodysplastic syndromeDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →